Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma

Journal of Clinical Investigation(2024)10.1172/jci171063Source: DataRank Database

The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma is a research paper published in Journal of Clinical Investigation (2024). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 4.38)OA: goldTopics (38)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Ailish Hanly,Frederick Gibson ORCID,Robert Fisher ORCID,Samantha Rogers ORCID,Kihyun Park ORCID

Live enrichment

PubMed:38300709 PMC:PMC10940100 OpenAlex:https://openalex.org/W4391450925

Karin Grunebaum Cancer Foundation

Grant: Research Award to Dr. Muzhou Wu

National Institutes of Health

Grant: R37GM62437

Melanoma Research Alliance

Grant: Established Investigator Award,(MRA 622586).

NIGMS NIH HHS

Grant: R37 GM062437

National Institutes of Health

Grant: 5R37GM062437-23

Protein Acylation and Methylation Mechanisms

FWCI

4.38

Citation Percentile

1.0%

Citation Trend

2022

2024

2025

2026

goldLicense: cc-by

journalhttp://www.jci.org/articles/view/171063/files/pdf

publisherhttp://www.jci.org/articles/view/171063/files/pdf

publisherhttps://www.jci.org/articles/view/171063/files/pdf

journalhttps://doi.org/10.1172/jci171063

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38300709

Fields of Study

Genomics and Chromatin DynamicsEpigenetics and DNA MethylationUbiquitin and proteasome pathways0301 basic medicine03 medical and health sciences

MeSH Terms

HumansMelanomaPhenotypeDrug Resistance, NeoplasmCell Line, TumorProtein Kinase Inhibitorsp38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins B-rafCo-Repressor Proteins

Keywords

RepressorPhenotypeMelanomaCancer researchResistance (ecology)Cell biologyBiologyImmunologyChemistryGeneticsTranscription factorGeneDrug therapyOncologyEpigeneticsDermatologyProto-Oncogene Proteins B-rafDrug Resistance, NeoplasmCell Line, TumorHumansCo-Repressor ProteinsProtein Kinase Inhibitorsp38 Mitogen-Activated Protein KinasesResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 5 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707346.v1figshare

Additional file 5 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707346figshare

Additional file 6 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707349figshare

Additional file 3 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707340.v1figshare

Additional file 4 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707343figshare

Additional file 6 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707349.v1figshare

Additional file 4 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707343.v1figshare

Additional file 3 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.26707340figshare

Additional file 2 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.25622043figshare

Additional file 1 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.25621891figshare

Additional file 1 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.25621891.v1figshare

Additional file 2 of Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence

10.6084/m9.figshare.25622043.v1figshare

The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma

FAIR Checklist

Authors (18)

Funding (5 grants)

Impact

Open Access

Topics

Linked Datasets (12)

Annotations (Europe PMC)